Don't Jump on This Chinese Peer-to-Peer Bandwagon

Related Link: 

Shares in Chinese peer-to-peer lender Yirendai have more than tripled in a few months. But that just raises questions about the risks the company takes on.

Sovereign Default: It's Not Personal, Just Business

Related Link: 

As governments in Greece and Puerto Rico grapple with heavy debts and struggling economies, there is a growing acceptance that restructuring of sovereign debt needs to be part of the solution, writes Greg Ip.

Regeneron Named as Science Talent Search Sponsor

Related Link: 

Regeneron Pharmaceuticals was selected as the new named sponsor of the Science Talent Search.

Dollar General: Why This Buck Goes a Long Way

Related Link: 

Dollar General has more than held its own nearly a year after Dollar Tree completed its deal for Family Dollar.

Microsoft to Streamline Smartphone Business

Related Link: 

Microsoft will lay off 1,850 workers and take an impairment and restructuring charge of approximately $950 million as it takes further step in dismantling the mobile-phone operations it acquired from Nokia.

Exxon, Chevron Shareholders Reject Climate-Change Stress Tests

Related Link: 

Shareholders at Exxon Mobil and Chevron narrowly voted down resolutions calling for stress tests to determine the risk that efforts to curb climate change pose to their businesses.

Insurers Seek Big Premium Boosts

Related Link: 

Big health plans stung by losses in the first few years of the U.S. health law’s implementation are seeking hefty premium increases for individual plans sold through insurance exchanges in more than a dozen states.

Alibaba SEC Probe: The Red Flags Fly Higher

Related Link: 

Alibaba’s revelation that it is being investigated for accounting practices hammers home for investors risks about the company.

Hewlett Packard and Microsoft: Why Focus Is In, Scale Is Out

Related Link: 

Downsizing at big tech companies is a cautionary tale that size doesn’t always win.

Gilead: What the Stock Needs to Bounce Back

Related Link: 

Gilead’s leadership refresh isn’t a cure-all for the stock’s troubles.

Syndicate content